1. Evidence on Immediate Next-Cycle vs. Delayed FET (Live Birth, Miscarriage, Patient Outcomes)
Across two independent systematic reviews and meta-analyses — Bergenheim et al. (Human Reproduction Update, 2021; 15 cohort studies, n=20,155 FET cycles) and Matorras et al. (Reproductive Medicine and Biology, 2021; 11 studies, n=11,500 cycles) — performing FET in the very first menstrual cycle after an unsuccessful transfer or stimulated cycle is non-inferior to postponing transfer for ≥1 washout cycle, with Bergenheim et al. reporting a slightly higher adjusted live birth rate for immediate FET (aOR 1.20, 95% CI 1.01–1.44) and Matorras et al. finding equivalent pooled live birth rates (RR 1.05, 95% CI 0.95–1.15).
In the only multicenter randomized controlled trial conducted specifically in women immediately following a failed embryo transfer attempt, Song et al. (Reproductive Biology and Endocrinology, 2021; n=732 randomized, n=646 completed FETs) compared immediate FET in the first menstrual cycle against delayed FET in the third or subsequent cycle. Immediate FET yielded a significantly higher clinical pregnancy rate (41.7% vs. 34.1%, RR 1.23, p=0.045), lower biochemical pregnancy loss (11.7% vs. 30.6%, RR 0.28, p<0.001), and a non-significant trend toward higher live birth (35.5% vs. 29.0%, p=0.075). Patient-reported psychological outcomes significantly favored immediate transfer, with lower pre-transfer moderate-to-severe depression (6.1% vs. 10.6%, p=0.038) and lower high perceived stress (22.4% vs. 30.3%, p=0.022). A parallel RCT following stimulated cycles by Li et al. (Human Reproduction, 2021; n=724) similarly reported higher live birth (47.2% vs. 37.7%, p=0.012) and lower miscarriage (13.2% vs. 24.2%, p=0.006) in immediate versus delayed FET.
2. Evidence That Storage Duration Does Not Affect Blastocyst Survival, Implantation, or Live Birth
Because the remaining blastocyst already exists and is vitrified in liquid nitrogen at −196°C, all cellular and enzymatic activity is suspended. In a multicenter cohort of 58,001 vitrified-warmed blastocyst transfer cycles, Cimadomo, Cobo et al. (American Journal of Obstetrics and Gynecology, 2024; n=58,001) demonstrated that once adjusted for maternal age at the time the embryo was created, cryostorage duration (from ≤2 months up to >34 months) has zero adverse effect on warming survival, implantation, miscarriage, live birth rate, or neonatal birthweight.
Complementing these cryobiology data, Huang et al. (Reproductive BioMedicine Online, 2023; n=5,995 patients) analyzed inter-transfer intervals across ≤40 days, 41–180 days (1.5–6 months), and >180 days across natural, letrozole-stimulated, and programmed HRT protocols, confirming identical adjusted live birth and perinatal outcomes between immediate (≤40 days) and 1.5–6 month intervals. Horowitz et al. (Reproductive BioMedicine Online, 2019; n=198 women up to age 45) likewise showed identical follicular phase dynamics, endometrial thickness, and live birth rates between immediate modified natural-cycle FET (mean 15.6 days to trigger) and delayed transfer (mean 84.8 days). Waiting 1–3 months therefore imposes zero biological penalty on the vitrified embryo or on uterine receptivity.
3. Modifiable Uterine, Endocrine, and Psychological Factors That Justify an Interval
Uterine Cavity & Chronic Endometritis (Moderate observational/meta-analytic evidence, T1/T3): In a systematic review and meta-analysis of 796 patients with implantation failure, Vitagliano et al. (Fertility and Sterility, 2018; n=796) showed that biopsy-diagnosed chronic endometritis (CD138 immunohistochemistry) treated and cured with a 14-day antibiotic course significantly increased live birth rates compared with persistent endometritis (OR 6.81, 95% CI 2.08–22.24), restoring outcomes to match unaffected controls. When only one blastocyst remains and the cavity has not recently been inspected, pausing 1–2 cycles for office hysteroscopy and CD138 testing is a concrete, evidence-supported use of an interval. By contrast, delaying transfer solely to perform a commercial Endometrial Receptivity Analysis (ERA) mock-cycle biopsy is refuted by high-certainty RCT evidence: Doyle et al. (JAMA, 2022; n=767) found no benefit in live birth (58.5% vs. 61.9%, p=0.38).
Endometrial Preparation Protocol, Luteal Progesterone & Thyroid (Prospective cohort evidence, T3): In ovulatory women, transferring in a natural or modified-natural cycle preserves the corpus luteum (which secretes vasoactive relaxin and VEGF); von Versen-Höynck et al. (Hypertension, 2019; n=683) demonstrated that programmed HRT cycles lacking a corpus luteum carried a significantly higher risk of pre-eclampsia (12.8% vs. 3.9%, adjusted OR 2.73). If the failed cycle was a programmed HRT protocol, taking one recovery bleed allows the hypothalamic-pituitary-ovarian axis to resume clean spontaneous ovulation. Regardless of whether FET is immediate or delayed, Labarta et al. (Human Reproduction, 2017, n=211; 2021, n=574) showed that low serum progesterone (<9.2 ng/mL) on transfer day reduces ongoing pregnancy from 52.8% to 32.7%, and that adding subcutaneous progesterone (25 mg/day) rescues live birth to 44.9% (vs. 45.0% in normal-P4 controls). Correcting an elevated thyroid TSH to <2.5 mIU/L requires 4–6 weeks of levothyroxine adjustment and justifies a 1–2 month wait; similarly, if the couple feels emotionally exhausted, Cimadomo et al. (2024) guarantees that taking 1–3 months for psychological recovery carries zero embryo cost.